

Executive Summary of Collaborative Working Project between Astellas Pharma Ltd and Addenbrookes Hospital:

Service Optimisation of the AML Diagnostic Testing Pathway

Date April 2024

Objective:

To undertake a “service review of the AML Diagnostic Testing Pathway” in partnership with Astellas Pharma Ltd, Bionical Solutions Ltd and *Addenbrookes Hospital* to support the re-design of that pathway to optimise the cancer centre’s AML Diagnostic Testing Pathway.

Summary:

Genetic testing for AML gene mutations is essential in the management of AML and should be carried out immediately to inform treatment decisions and allow a timely initiation of a treatment. Not only at initial diagnosis but also at relapse, data shows the importance of the testing for actionable gene mutations where there are poor patient outcomes.

With such importance of testing, the efficient referral and testing pathways are an important part of successful AML patient management, especially for elderly patients.

The AML Diagnostic Testing Pathway Service Optimisation programme will enable cancer centres to work in partnership with Astellas/Bionical Solutions to review this part of the pathway to identify any inefficiencies, wastage, delays & bottlenecks etc. that may be causing an ineffective service.

Astellas are committed to supporting the NHS with AML diagnostic testing pathway. By working in partnership, Astellas are at the forefront of driving innovation and change for the positive benefit of patients and assisting the NHS in delivering high standards of care. Working in partnership between Astellas, Bionical Solutions and cancer centres, pooling of joint expertise to review this part of the pathway, will support health professionals in their desire to improve patient well-being.

Benefits of Project

Patients	<ul style="list-style-type: none">• Potential efficiencies in time to diagnosis and appropriate treatment decisions for patients.• Potential reduction in diagnostic testing turnaround times allowing MDT to review individual patient results collectively.• Potentially may lead to a more beneficial patient experience from diagnosis to initiation of treatment and ongoing management.
NHS	<ul style="list-style-type: none">• Service optimisation may lead to improved service delivery and improvement of the AML diagnostic testing pathway.• Enhanced testing turnaround times within the AML diagnostic testing pathway.• An efficient service will lead to a more sustainable service.

<p>Astellas Pharma Ltd</p>	<ul style="list-style-type: none"> • Recognition of Astellas offering value added services that benefit NHS within the AML diagnostic testing pathway. • Development of relationships with cancer centres through working in partnership to solve unmet needs. • Enhancing skill base of service re-design expertise in-house.
--------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------